DE60201437T2 - 2,6-substituierte chromanderivate und ihre verwendung als beta-3 adrenorezeptor agonisten - Google Patents

2,6-substituierte chromanderivate und ihre verwendung als beta-3 adrenorezeptor agonisten Download PDF

Info

Publication number
DE60201437T2
DE60201437T2 DE60201437T DE60201437T DE60201437T2 DE 60201437 T2 DE60201437 T2 DE 60201437T2 DE 60201437 T DE60201437 T DE 60201437T DE 60201437 T DE60201437 T DE 60201437T DE 60201437 T2 DE60201437 T2 DE 60201437T2
Authority
DE
Germany
Prior art keywords
amino
methyl
dihydro
chromen
pyridinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60201437T
Other languages
German (de)
English (en)
Other versions
DE60201437D1 (de
Inventor
J. Stephen O'CONNOR
H. Gaetan LADOUCEUR
H. William BULLOCK
Ann-Marie Campbell
Miao Dai
Robert Dally
Jacques Dumas
N. Holia HATOUM-MOKDAD
Uday Khire
Wendy Lee
Qingjie Liu
B. Derek LOWE
R. Steven MAGNUSON
Ning Qi
E. Tatiana SHELEKHIN
Quanrong Shen
A. Roger SMITH
Ming Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharmaceuticals Corp
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of DE60201437D1 publication Critical patent/DE60201437D1/de
Application granted granted Critical
Publication of DE60201437T2 publication Critical patent/DE60201437T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60201437T 2001-04-23 2002-04-22 2,6-substituierte chromanderivate und ihre verwendung als beta-3 adrenorezeptor agonisten Expired - Fee Related DE60201437T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28571901P 2001-04-23 2001-04-23
US285719P 2001-04-23
US32451801P 2001-09-26 2001-09-26
US324518P 2001-09-26
PCT/US2002/012940 WO2002085891A1 (en) 2001-04-23 2002-04-22 2,6-substituted chroman derivatives useful as beta-3 adrenoreceptor agonists

Publications (2)

Publication Number Publication Date
DE60201437D1 DE60201437D1 (de) 2004-11-04
DE60201437T2 true DE60201437T2 (de) 2005-12-15

Family

ID=26963345

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60201437T Expired - Fee Related DE60201437T2 (de) 2001-04-23 2002-04-22 2,6-substituierte chromanderivate und ihre verwendung als beta-3 adrenorezeptor agonisten

Country Status (9)

Country Link
US (3) US6660752B2 (enExample)
EP (1) EP1389202B1 (enExample)
JP (1) JP2004532227A (enExample)
AR (1) AR035858A1 (enExample)
DE (1) DE60201437T2 (enExample)
DO (1) DOP2002000385A (enExample)
ES (1) ES2230487T3 (enExample)
PE (1) PE20021073A1 (enExample)
WO (1) WO2002085891A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049593A2 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
BRPI0510642A (pt) * 2004-05-05 2007-11-20 Hoffmann La Roche arilsulfonil benzodioxanos úteis para modulação do receptor de 5-ht6, do receptor de 5ht2a ou ambos
CA2591793A1 (en) * 2004-12-21 2006-06-29 F. Hoffmann-La Roche Ag Tetralin and indane derivatives and uses thereof
EP1831203A1 (en) 2004-12-21 2007-09-12 F. Hoffmann-Roche AG Chroman derivatives and uses thereof in the treatment of cns disorders
MX2007007482A (es) * 2004-12-21 2007-07-20 Hoffmann La Roche Derivados de tetralina e indano y usos de los mismos como antagonistas de 5-ht.
RU2396255C2 (ru) * 2004-12-21 2010-08-10 Ф. Хоффманн-Ля Рош Аг Производные тетралина и индана и их применения
DE602005007064D1 (de) * 2004-12-21 2008-07-03 Hoffmann La Roche Chromanderivate und ihre verwendung als liganden des 5-ht-rezeptors
AR052674A1 (es) 2005-02-17 2007-03-28 Wyeth Corp Derivados de indol, benzotiofeno, benzofurano e indeno cicloalquilcondensados
WO2007051735A1 (en) 2005-11-03 2007-05-10 F. Hoffmann-La Roche Ag Arylsulfonylchromans as 5-ht6 inhibitors indolylmaleimide derivatives as protein kinase inhibitors
GB0526252D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
SI2402317T1 (sl) 2006-03-31 2013-10-30 Novartis Ag DGAT inhibitor
JP2009541249A (ja) * 2006-06-20 2009-11-26 エフ．ホフマン−ラ ロシュ アーゲー アリールスルホニルナフタレン誘導体およびその使用
KR101064001B1 (ko) * 2006-06-20 2011-09-08 에프. 호프만-라 로슈 아게 아릴설폰아미딜 테트랄린 유도체 및 이의 용도
MX2008015843A (es) * 2006-06-20 2009-01-09 Hoffmann La Roche Derivados de tetralina e indano y usos de los mismos.
MY166890A (en) 2011-08-30 2018-07-24 Chdi Foundation Inc Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
CN107488154B (zh) * 2013-01-09 2021-04-27 巴斯夫农业公司 制备取代环氧乙烷类和三唑类的方法
US9790231B2 (en) * 2013-06-24 2017-10-17 Lupin Limited Chromane and chromene derivatives and their use as CRAC modulators
WO2015003908A1 (en) 2013-07-08 2015-01-15 Basf Se Compositions comprising a triazole compound and a biopesticide
EA037646B1 (ru) * 2013-12-12 2021-04-27 Басф Агро Б.В. Способ получения замещенных триазолов
BR112016030116B1 (pt) 2014-06-25 2021-07-06 BASF Agro B.V. composições, uso de uma composição, método para o combate dos fungos e material de propagação dos vegetais
US10053436B2 (en) 2014-07-08 2018-08-21 BASF Agro B.V. Process for the preparation of substituted oxiranes and triazoles
JP2017520610A (ja) 2014-07-17 2017-07-27 シーエイチディーアイ ファウンデーション，インコーポレーテッド Ｈｉｖ関連障害を治療するための方法及び組成物
UA120628C2 (uk) 2014-11-07 2020-01-10 Басф Се Пестицидні суміші
WO2016180642A1 (en) 2015-05-08 2016-11-17 BASF Agro B.V. A process for the preparation of terpinolene epoxide
DK3294700T3 (da) 2015-05-08 2020-04-14 Basf Agro Bv Fremgangsmåde til fremstilling af limonen-4-ol
WO2017095723A1 (en) * 2015-11-30 2017-06-08 Merck Sharp & Dohme Corp. Aryl acylsulfonamides as blt1 antagonists
US10336733B2 (en) 2015-11-30 2019-07-02 Merk Sharp & Dohme Corp. Aryl acylsulfonamides as BLT1 antagonists
WO2017157910A1 (en) 2016-03-16 2017-09-21 Basf Se Use of tetrazolinones for combating resistant phytopathogenic fungi on cereals
BR112018068695B1 (pt) 2016-03-16 2022-12-27 Basf Se Uso de um composto e método para controlar fungos fitopatogênicos
BR112018068705B1 (pt) 2016-03-16 2022-09-06 Basf Se Método para controlar fungos fitopatogênicos
MX2018015764A (es) 2016-06-15 2019-08-29 Basf Agro Bv Proceso para la epoxidacion de un alqueno tetrasustituido.
AU2017284971B2 (en) 2016-06-15 2021-01-21 BASF Agro B.V. Process for the epoxidation of a tetrasubstituted alkene
GB201803394D0 (en) * 2018-03-02 2018-04-18 Inflazome Ltd Novel compounds
WO2024040267A2 (en) * 2022-08-19 2024-02-22 Mitokinin, Inc. Direct synthesis of n-(3-substituted-chroman-4-yl)-7h- pyrrolo[2,3-d]pyrimidin-4-amines and derivatives thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3706764A (en) 1969-04-16 1972-12-19 Yoshitomi Pharmaceutical Phenethylaminomethyl-chromanones and- thiochromanones
US3803176A (en) 1969-05-09 1974-04-09 Novo Terapeutisk Labor As Sulfonylurea derivatives
GB1499323A (en) 1974-03-22 1978-02-01 Fisons Ltd 6-substituted chromones and chromanones
ATE25251T1 (de) 1981-11-12 1987-02-15 Fisons Plc Anti srs-a carbonsaeure-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische formulierungen.
EP0091749A3 (en) 1982-04-08 1984-12-05 Beecham Group Plc Ethanolamine derivatives, process for their preparation and pharmaceutical compositions containing them
ZA844519B (en) 1983-06-24 1985-02-27 Hoffmann La Roche Dihydrobenzopyran derivatives
US4654362A (en) 1983-12-05 1987-03-31 Janssen Pharmaceutica, N.V. Derivatives of 2,2'-iminobisethanol
DE3411992A1 (de) 1984-03-31 1985-10-10 Bayer Ag, 5090 Leverkusen Substituierte 4-hydroxy-benzopyrane, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
US4727877A (en) * 1984-12-18 1988-03-01 Medtronic, Inc. Method and apparatus for low energy endocardial defibrillation
GB8801306D0 (en) 1988-01-21 1988-02-17 Ici Plc Chemical compounds
US5117824A (en) * 1990-11-14 1992-06-02 Medtronic, Inc. Apparatus for monitoring electrical physiologic signals
US5163427A (en) * 1990-11-14 1992-11-17 Medtronic, Inc. Apparatus for delivering single and multiple cardioversion and defibrillation pulses
US5129392A (en) * 1990-12-20 1992-07-14 Medtronic, Inc. Apparatus for automatically inducing fibrillation
FR2695387B1 (fr) 1992-09-09 1994-10-21 Adir Nouveaux composés benzopyraniques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
US5451677A (en) 1993-02-09 1995-09-19 Merck & Co., Inc. Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
WO1994029290A1 (en) 1993-06-14 1994-12-22 Pfizer Inc. Secondary amines as antidiabetic and antiobesity agents
GB9405019D0 (en) 1994-03-15 1994-04-27 Smithkline Beecham Plc Novel compounds
US5541197A (en) 1994-04-26 1996-07-30 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
US5561142A (en) 1994-04-26 1996-10-01 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
IL113410A (en) 1994-04-26 1999-11-30 Merck & Co Inc Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them
US5516917A (en) 1994-06-08 1996-05-14 G. D. Searle & Co. Leukotriene B4 antagonists
JPH08198866A (ja) 1995-01-20 1996-08-06 Tokyo Tanabe Co Ltd 新規２−アミノ−１−フェニルエタノール化合物
US5674254A (en) * 1995-05-22 1997-10-07 Vitatron Medical, B.V. Cardiac pacemaker system and method for determining a measure of pacing threshold without incurring loss of capture
US5663194A (en) 1995-07-25 1997-09-02 Mewshaw; Richard E. Chroman-2-ylmethylamino derivatives
ZA967892B (en) 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
FR2746395B1 (fr) * 1996-03-22 1998-04-17 Adir Nouveaux derives d'arylethanolamine et d'aryloxypropanolamine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP3708624B2 (ja) 1996-03-27 2005-10-19 キッセイ薬品工業株式会社 ３，４−ジ置換フェニルエタノールアミノテトラリンカルボン酸誘導体
EP0801060A1 (en) 1996-04-09 1997-10-15 Pfizer Inc. Heterocyclic Beta-3 Adrenergenic Agonists
WO1997046556A1 (en) 1996-06-07 1997-12-11 Merck & Co., Inc. OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY
HUP0002053A3 (en) 1997-01-28 2001-09-28 Merck & Co Inc Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity
US5741312A (en) * 1997-03-12 1998-04-21 Vitatron Medical, B.V. Pacemaker system and method with improved capture detection and threshold search
US6051586A (en) 1997-12-19 2000-04-18 Bayer Corporation Sulfonamide substituted chroman derivatives useful as beta 3 adrenoreceptor agonists
RU2223269C2 (ru) * 1997-12-19 2004-02-10 Байер Корпорейшн Производные хромана, промежуточные соединения, фармацевтическая композиция и способы лечения.
US6469031B1 (en) * 1998-12-18 2002-10-22 Bayer Corporation Carboxyl substituted chroman derivatives useful as beta 3 adrenoreceptor agonists
US6052621A (en) * 1998-01-27 2000-04-18 Vitatron Medical B.V. System and method for inducing tachycardia
GB9812709D0 (en) 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds
DE60029776T2 (de) * 1999-05-12 2007-08-02 Medtronic, Inc., Minneapolis Überwachungsvorrichtung mit anwendung von wavelettransformationen zur herzrrhythmusanalyse
US6647292B1 (en) * 2000-09-18 2003-11-11 Cameron Health Unitary subcutaneous only implantable cardioverter-defibrillator and optional pacer
US6675042B2 (en) * 2002-04-15 2004-01-06 Charles D. Swerdlow Defibrillation shock strength determination technology

Also Published As

Publication number Publication date
AR035858A1 (es) 2004-07-21
DOP2002000385A (es) 2004-01-31
US6660752B2 (en) 2003-12-09
US20030078260A1 (en) 2003-04-24
US20040072828A1 (en) 2004-04-15
EP1389202A1 (en) 2004-02-18
JP2004532227A (ja) 2004-10-21
WO2002085891A1 (en) 2002-10-31
US6919371B2 (en) 2005-07-19
DE60201437D1 (de) 2004-11-04
PE20021073A1 (es) 2002-12-12
EP1389202B1 (en) 2004-09-29
ES2230487T3 (es) 2005-05-01
US20050215594A1 (en) 2005-09-29

Similar Documents

Publication Publication Date Title
DE60201437T2 (de) 2,6-substituierte chromanderivate und ihre verwendung als beta-3 adrenorezeptor agonisten
DE69324354T2 (de) Neue benzopyranderivate
TWI588136B (zh) 多環類衍生物、其製備方法及其在醫藥上的應用
DE60120138T2 (de) Amid-verbindungen und deren verwendung
EP0298452A2 (de) In 4-Stellung durch Aryl oder N-Heteroaryl substituierte 2H-1-Benzopyran-Derivate
US6780859B2 (en) Benzofuran and dihydrobenzofuran derivatives useful as beta-3 adrenoreceptor agonists
US6699860B2 (en) Di-substituted aminomethyl-chroman derivative beta-3 adrenoreceptor agonists
WO2005046683A1 (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
DE69807523T2 (de) Carboxylsubstituierte chromanderivate zur verwendung als beta 3 adrenorezeptor-agonisten
AU751015B2 (en) Novel sulfonamide substituted chroman derivatives useful as beta-3 adrenoreceptor agonists
DE69518322T2 (de) C-4 amid substituierte verbindungen und deren verwendung als therapeutische mittel
US20040072843A1 (en) Novel sulfonamide substituted chroman derivatives useful as beta 3 adrenoreceptor agonists
WO2005066131A1 (en) Non-nucleotide reverse transcriptase inhibitors
US6469031B1 (en) Carboxyl substituted chroman derivatives useful as beta 3 adrenoreceptor agonists
DE10120619A1 (de) 2-(5-(4-Fluorphenyl)-3-pyridylmethylaminomethyl-chroman
DE69422038T2 (de) Benzopyranderivate
CZ20002257A3 (cs) Karboxysubstituované chromanové deriváty, které lze použít jako beta-3-adrenoreceptorové agonisty
DE102005039145A1 (de) Substituierte benzokondensierte Cyclohexanon-Derivate und deren Verwendung zur Herstellung von Arzneimitteln
KR20040028769A (ko) 카텝신 억제제로서의 화합물 및 조성물
OA17714A (en) Anthelmintic compounds and compositions and method of using thereof.
HK1034973A (en) Carboxyl substituted chroman derivatives useful as beta 3 adrenoreceptor agonists

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee